Vertex Presents Positive Long-Term Data On CASGEVY® (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress.

BOSTON --(BUSINESS WIRE) - June 14, 2024 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY® (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved CRISPR-based gene-editing therapy. The data being presented are from more than 100...